4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

24-10-2013 Motley Fool UKComments (0)


AstraZeneca currently trades at a historic P/E ratio of 7.9, below the biotechnology sector average of 17.1. However, as the company is set to lose the exclusive manufacturing rights to a number of treatments during the next few years, City analysts ...

Read more on Motley Fool UK

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top